Many people in the industry are interested in the extent to which pharmacogenomic testing is actually being used in medical practice. The cytochrome enzyme, CYP2D6, is responsible for the metabolism of approximately 25% of all commonly prescribed drugs. Many of these drugs have a narrow therapeutic index including cardiovascular, central nervous system, and analgesics. Patients who are Poor Metabolizers (approximately 7% of patients) are at significant risk of adverse drug reactions due to drug accumulation induced toxicity.
The question is: Does your laboratory currently offer CYP2D6 testing either as physician-referred or patient self-directed requests?
I think the answer to this question will help us evaluate whether this most obvious and important test is being incorporated into drug treatment in the US and elsewhere.
Thanks in advance for your posting.
MPM
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment